ID   NUCL_HUMAN              Reviewed;         710 AA.
AC   P19338; Q53SK1; Q8NB06; Q9UCF0; Q9UDG1;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   28-JUN-2023, entry version 239.
DE   RecName: Full=Nucleolin;
DE   AltName: Full=Protein C23;
GN   Name=NCL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Retina;
RX   PubMed=2737305; DOI=10.1016/0014-5793(89)80692-1;
RA   Srivastava M., Fleming P.J., Pollard H.B., Burns A.L.;
RT   "Cloning and sequencing of the human nucleolin cDNA.";
RL   FEBS Lett. 250:99-105(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2394707; DOI=10.1016/s0021-9258(18)77205-0;
RA   Srivastava M., McBride O.W., Fleming P.J., Pollard H.B., Burns A.L.;
RT   "Genomic organization and chromosomal localization of the human nucleolin
RT   gene.";
RL   J. Biol. Chem. 265:14922-14931(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Hair follicle dermal papilla;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   PROTEIN SEQUENCE OF 2-7; 349-362 AND 610-624.
RC   TISSUE=Lymphoma;
RX   PubMed=7718615; DOI=10.1016/0167-4889(95)00028-q;
RA   Krantz S., Salazar R., Brandt R., Kellermann J., Lottspeich F.;
RT   "Purification and partial amino acid sequencing of a fructosyllysine-
RT   specific binding protein from cell membranes of the monocyte-like cell line
RT   U937.";
RL   Biochim. Biophys. Acta 1266:109-112(1995).
RN   [6]
RP   PROTEIN SEQUENCE OF 231-236; 349-362; 399-403; 458-461 AND 649-653.
RX   PubMed=7993898; DOI=10.1021/bi00253a007;
RA   Jordan P., Heid H., Kinzel V., Kubler D.;
RT   "Major cell surface-located protein substrates of an ecto-protein kinase
RT   are homologs of known nuclear proteins.";
RL   Biochemistry 33:14696-14706(1994).
RN   [7]
RP   PROTEIN SEQUENCE OF 458-474, AND NUCLEOTIDE-BINDING.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=8321232; DOI=10.1128/mcb.13.7.4301-4310.1993;
RA   Ishikawa F., Matunis M.J., Dreyfuss G., Cech T.R.;
RT   "Nuclear proteins that bind the pre-mRNA 3' splice site sequence r(UUAG/G)
RT   and the human telomeric DNA sequence d(TTAGGG)n.";
RL   Mol. Cell. Biol. 13:4301-4310(1993).
RN   [8]
RP   FUNCTION, AND IDENTIFICATION IN A COMPLEX WITH HTATSF1; CCNT1; RNA
RP   POLYMERASE II; SUPT5H AND CDK9.
RX   PubMed=10393184; DOI=10.1093/emboj/18.13.3688;
RA   Parada C.A., Roeder R.G.;
RT   "A novel RNA polymerase II-containing complex potentiates Tat-enhanced HIV-
RT   1 transcription.";
RL   EMBO J. 18:3688-3701(1999).
RN   [9]
RP   INTERACTION WITH MDK.
RX   PubMed=12147681; DOI=10.1074/jbc.m201194200;
RA   Said E.A., Krust B., Nisole S., Svab J., Briand J.P., Hovanessian A.G.;
RT   "The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin
RT   as a low affinity receptor.";
RL   J. Biol. Chem. 277:37492-37502(2002).
RN   [10]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12429849; DOI=10.1091/mbc.e02-05-0271;
RA   Scherl A., Coute Y., Deon C., Calle A., Kindbeiter K., Sanchez J.-C.,
RA   Greco A., Hochstrasser D.F., Diaz J.-J.;
RT   "Functional proteomic analysis of human nucleolus.";
RL   Mol. Biol. Cell 13:4100-4109(2002).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [12]
RP   INTERACTION WITH APTX.
RX   PubMed=15044383; DOI=10.1093/hmg/ddh122;
RA   Gueven N., Becherel O.J., Kijas A.W., Chen P., Howe O., Rudolph J.H.,
RA   Gatti R., Date H., Onodera O., Taucher-Scholz G., Lavin M.F.;
RT   "Aprataxin, a novel protein that protects against genotoxic stress.";
RL   Hum. Mol. Genet. 13:1081-1093(2004).
RN   [13]
RP   INTERACTION WITH TERT.
RX   PubMed=15371412; DOI=10.1074/jbc.m407643200;
RA   Khurts S., Masutomi K., Delgermaa L., Arai K., Oishi N., Mizuno H.,
RA   Hayashi N., Hahn W.C., Murakami S.;
RT   "Nucleolin interacts with telomerase.";
RL   J. Biol. Chem. 279:51508-51515(2004).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-145; SER-153 AND SER-563, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-580, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-145; SER-153; SER-184 AND
RP   SER-206, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Prostate cancer;
RX   PubMed=17487921; DOI=10.1002/elps.200600782;
RA   Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.;
RT   "Toward a global characterization of the phosphoproteome in prostate cancer
RT   cells: identification of phosphoproteins in the LNCaP cell line.";
RL   Electrophoresis 28:2027-2034(2007).
RN   [17]
RP   INTERACTION WITH GZF1, AND SUBCELLULAR LOCATION.
RX   PubMed=17674968; DOI=10.1016/j.yexcr.2007.07.003;
RA   Dambara A., Morinaga T., Fukuda N., Yamakawa Y., Kato T., Enomoto A.,
RA   Asai N., Murakumo Y., Matsuo S., Takahashi M.;
RT   "Nucleolin modulates the subcellular localization of GDNF-inducible zinc
RT   finger protein 1 and its roles in transcription and cell proliferation.";
RL   Exp. Cell Res. 313:3755-3766(2007).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-76 AND THR-121, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells
RT   and high confident phosphopeptide identification by cross-validation of
RT   MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [19]
RP   INTERACTION WITH NSUN2.
RX   PubMed=17215513; DOI=10.1091/mbc.e06-11-1021;
RA   Sakita-Suto S., Kanda A., Suzuki F., Sato S., Takata T., Tatsuka M.;
RT   "Aurora-B regulates RNA methyltransferase NSUN2.";
RL   Mol. Biol. Cell 18:1107-1117(2007).
RN   [20]
RP   IDENTIFICATION IN A MRNP GRANULE COMPLEX, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND SUBCELLULAR LOCATION.
RX   PubMed=17289661; DOI=10.1074/mcp.m600346-mcp200;
RA   Joeson L., Vikesaa J., Krogh A., Nielsen L.K., Hansen T., Borup R.,
RA   Johnsen A.H., Christiansen J., Nielsen F.C.;
RT   "Molecular composition of IMP1 ribonucleoprotein granules.";
RL   Mol. Cell. Proteomics 6:798-811(2007).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-67; THR-69; SER-184; SER-206
RP   AND THR-214, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [23]
RP   INTERACTION WITH RRP1B.
RX   PubMed=19710015; DOI=10.1074/jbc.m109.023457;
RA   Crawford N.P., Yang H., Mattaini K.R., Hunter K.W.;
RT   "The metastasis efficiency modifier ribosomal RNA processing 1 homolog B
RT   (RRP1B) is a chromatin-associated factor.";
RL   J. Biol. Chem. 284:28660-28673(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-28; SER-34 AND THR-301, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [25]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-9; LYS-102; LYS-116; LYS-124;
RP   LYS-318; LYS-377; LYS-398; LYS-403; LYS-513; LYS-572; LYS-577 AND LYS-646,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH ERBB4, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=20858735; DOI=10.1158/1541-7786.mcr-10-0042;
RA   Gilmore-Hebert M., Ramabhadran R., Stern D.F.;
RT   "Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage
RT   response pathways.";
RL   Mol. Cancer Res. 8:1388-1398(2010).
RN   [27]
RP   INTERACTION WITH ZFP36.
RX   PubMed=20221403; DOI=10.1371/journal.pone.0009588;
RA   Kedar V.P., Darby M.K., Williams J.G., Blackshear P.J.;
RT   "Phosphorylation of human tristetraprolin in response to its interaction
RT   with the Cbl interacting protein CIN85.";
RL   PLoS ONE 5:E9588-E9588(2010).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-28; SER-34; SER-67; THR-69;
RP   THR-76; THR-84; THR-92; THR-99; THR-106; THR-113; THR-121; SER-145; SER-563
RP   AND SER-619, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   SUBUNIT, INTERACTION WITH RIOK1, AND METHYLATION BY PRTM5.
RX   PubMed=21081503; DOI=10.1074/jbc.m110.148486;
RA   Guderian G., Peter C., Wiesner J., Sickmann A., Schulze-Osthoff K.,
RA   Fischer U., Grimmler M.;
RT   "RioK1, a new interactor of protein arginine methyltransferase 5 (PRMT5),
RT   competes with pICln for binding and modulates PRMT5 complex composition and
RT   substrate specificity.";
RL   J. Biol. Chem. 286:1976-1986(2011).
RN   [31]
RP   INTERACTION WITH NVL.
RX   PubMed=21474449; DOI=10.1074/jbc.m110.174680;
RA   Fujiwara Y., Fujiwara K., Goda N., Iwaya N., Tenno T., Shirakawa M.,
RA   Hiroaki H.;
RT   "Structure and function of the N-terminal nucleolin binding domain of
RT   nuclear valosin-containing protein-like 2 (NVL2) harboring a nucleolar
RT   localization signal.";
RL   J. Biol. Chem. 286:21732-21741(2011).
RN   [32]
RP   INTERACTION WITH HNRNPU.
RX   PubMed=21242313; DOI=10.1242/jcs.063347;
RA   Ma N., Matsunaga S., Morimoto A., Sakashita G., Urano T., Uchiyama S.,
RA   Fukui K.;
RT   "The nuclear scaffold protein SAF-A is required for kinetochore-microtubule
RT   attachment and contributes to the targeting of Aurora-A to mitotic
RT   spindles.";
RL   J. Cell Sci. 124:394-404(2011).
RN   [33]
RP   INTERACTION WITH SETX.
RX   PubMed=21700224; DOI=10.1016/j.molcel.2011.04.026;
RA   Skourti-Stathaki K., Proudfoot N.J., Gromak N.;
RT   "Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause
RT   sites to promote Xrn2-dependent termination.";
RL   Mol. Cell 42:794-805(2011).
RN   [34]
RP   INTERACTION WITH C1QBP.
RX   PubMed=21536856; DOI=10.1074/mcp.m110.006148;
RA   Yoshikawa H., Komatsu W., Hayano T., Miura Y., Homma K., Izumikawa K.,
RA   Ishikawa H., Miyazawa N., Tachikawa H., Yamauchi Y., Isobe T.,
RA   Takahashi N.;
RT   "Splicing factor 2-associated protein p32 participates in ribosome
RT   biogenesis by regulating the binding of Nop52 and fibrillarin to
RT   preribosome particles.";
RL   Mol. Cell. Proteomics 10:0-0(2011).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-67; THR-69; SER-563; SER-580
RP   AND SER-619, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [36]
RP   INTERACTION WITH ALKBH2.
RX   PubMed=23972994; DOI=10.1016/j.celrep.2013.07.027;
RA   Li P., Gao S., Wang L., Yu F., Li J., Wang C., Li J., Wong J.;
RT   "ABH2 couples regulation of ribosomal DNA transcription with DNA alkylation
RT   repair.";
RL   Cell Rep. 4:817-829(2013).
RN   [37]
RP   INTERACTION WITH WDR46.
RX   PubMed=23848194; DOI=10.1111/gtc.12077;
RA   Hirai Y., Louvet E., Oda T., Kumeta M., Watanabe Y., Horigome T.,
RA   Takeyasu K.;
RT   "Nucleolar scaffold protein, WDR46, determines the granular compartmental
RT   localization of nucleolin and DDX21.";
RL   Genes Cells 18:780-797(2013).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-67; THR-76; THR-121; SER-145;
RP   SER-153; SER-184; SER-206; SER-356; THR-367; THR-405; SER-458; SER-460;
RP   SER-563; SER-580 AND SER-619, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41; SER-42; SER-67; SER-184;
RP   SER-580; SER-591 AND SER-619, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [41]
RP   INTERACTION WITH FMR1.
RX   PubMed=24658146; DOI=10.1371/journal.pone.0091465;
RA   Taha M.S., Nouri K., Milroy L.G., Moll J.M., Herrmann C., Brunsveld L.,
RA   Piekorz R.P., Ahmadian M.R.;
RT   "Subcellular fractionation and localization studies reveal a direct
RT   interaction of the fragile X mental retardation protein (FMRP) with
RT   nucleolin.";
RL   PLoS ONE 9:E91465-E91465(2014).
RN   [42]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-297; LYS-324 AND LYS-589, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [44]
RP   INTERACTION WITH HDGF.
RX   PubMed=26845719; DOI=10.1515/hsz-2015-0273;
RA   Nuesse J., Mirastschijski U., Waespy M., Oetjen J., Brandes N., Rebello O.,
RA   Paroni F., Kelm S., Dietz F.;
RT   "Two new isoforms of the human hepatoma-derived growth factor interact with
RT   components of the cytoskeleton.";
RL   Biol. Chem. 397:417-436(2016).
RN   [45]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-324; LYS-370; LYS-377; LYS-513;
RP   LYS-577; LYS-589 AND LYS-624, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [46]
RP   STRUCTURE BY NMR OF 478-566.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the RRM_1 domain of NCL protein.";
RL   Submitted (JUN-2006) to the PDB data bank.
CC   -!- FUNCTION: Nucleolin is the major nucleolar protein of growing
CC       eukaryotic cells. It is found associated with intranucleolar chromatin
CC       and pre-ribosomal particles. It induces chromatin decondensation by
CC       binding to histone H1. It is thought to play a role in pre-rRNA
CC       transcription and ribosome assembly. May play a role in the process of
CC       transcriptional elongation. Binds RNA oligonucleotides with 5'-UUAGGG-
CC       3' repeats more tightly than the telomeric single-stranded DNA 5'-
CC       TTAGGG-3' repeats. {ECO:0000269|PubMed:10393184}.
CC   -!- SUBUNIT: Identified in a IGF2BP1-dependent mRNP granule complex
CC       containing untranslated mRNAs (PubMed:17289661). Component of the SWAP
CC       complex that consists of NPM1, NCL/nucleolin, PARP1 and SWAP70 (By
CC       similarity). Component of a complex which is at least composed of
CC       HTATSF1/Tat-SF1, the P-TEFb complex components CDK9 and CCNT1, RNA
CC       polymerase II, SUPT5H, and NCL/nucleolin (PubMed:10393184). Interacts
CC       with AICDA (By similarity). Interacts with APTX (PubMed:15044383).
CC       Interacts with C1QBP (PubMed:21536856). Interacts with ERBB4
CC       (PubMed:20858735). Interacts (via C-terminus) with FMR1 isoform 6 (via
CC       N-terminus) (PubMed:24658146). Interacts with GZF1; this interaction is
CC       important for nucleolar localization of GZF1 (PubMed:17674968).
CC       Interacts with NSUN2 (PubMed:17215513). Interacts with NVL
CC       (PubMed:21474449). Interacts (via N-terminus domain) with SETX
CC       (PubMed:21700224). Interacts (via RRM1 and C-terminal RRM4/Arg/Gly-rich
CC       domains) with TERT; the interaction is important for nucleolar
CC       localization of TERT (PubMed:15371412). Interacts with WDR46
CC       (PubMed:23848194). Interacts with ZFP36 (PubMed:20221403). Interacts
CC       with LRRC34 (By similarity). Interacts with RRP1B (PubMed:19710015).
CC       Interacts with HNRNPU; this interaction occurs during mitosis
CC       (PubMed:21242313). Interacts with RIOK1; RIOK1 recruits NCL to PRMT5
CC       for symmetrically methylation (PubMed:21081503). Interacts with ZBTB7B
CC       (By similarity). Interacts with MDK; this interaction promotes NCL
CC       clustering and lateral movements of this complex into lipid rafts
CC       leading to MDK internalization (PubMed:12147681). Interacts with HDGF
CC       (isoform 1) (PubMed:26845719). Interacts with ALKBH2.
CC       {ECO:0000250|UniProtKB:P09405, ECO:0000269|PubMed:10393184,
CC       ECO:0000269|PubMed:12147681, ECO:0000269|PubMed:15044383,
CC       ECO:0000269|PubMed:15371412, ECO:0000269|PubMed:17215513,
CC       ECO:0000269|PubMed:17289661, ECO:0000269|PubMed:17674968,
CC       ECO:0000269|PubMed:19710015, ECO:0000269|PubMed:20221403,
CC       ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:21081503,
CC       ECO:0000269|PubMed:21242313, ECO:0000269|PubMed:21474449,
CC       ECO:0000269|PubMed:21536856, ECO:0000269|PubMed:21700224,
CC       ECO:0000269|PubMed:23848194, ECO:0000269|PubMed:23972994,
CC       ECO:0000269|PubMed:24658146, ECO:0000269|PubMed:26845719}.
CC   -!- INTERACTION:
CC       P19338; Q9Y6D6: ARFGEF1; NbExp=5; IntAct=EBI-346967, EBI-1044254;
CC       P19338; P49407: ARRB1; NbExp=3; IntAct=EBI-346967, EBI-743313;
CC       P19338; P32121: ARRB2; NbExp=3; IntAct=EBI-346967, EBI-714559;
CC       P19338; PRO_0000005794 [P39060]: COL18A1; NbExp=12; IntAct=EBI-346967, EBI-2566375;
CC       P19338; Q00987: MDM2; NbExp=8; IntAct=EBI-346967, EBI-389668;
CC       P19338; P35579: MYH9; NbExp=3; IntAct=EBI-346967, EBI-350338;
CC       P19338; P19338: NCL; NbExp=5; IntAct=EBI-346967, EBI-346967;
CC       P19338; Q9UQ80: PA2G4; NbExp=2; IntAct=EBI-346967, EBI-924893;
CC       P19338; Q06710: PAX8; NbExp=2; IntAct=EBI-346967, EBI-2683132;
CC       P19338; P61586: RHOA; NbExp=3; IntAct=EBI-346967, EBI-446668;
CC       P19338; P04637: TP53; NbExp=2; IntAct=EBI-346967, EBI-366083;
CC       P19338; P63104: YWHAZ; NbExp=2; IntAct=EBI-346967, EBI-347088;
CC       P19338; Q9CR42: Ankrd1; Xeno; NbExp=2; IntAct=EBI-346967, EBI-8308696;
CC       P19338; Q8AZK7: EBNA-LP; Xeno; NbExp=2; IntAct=EBI-346967, EBI-1185167;
CC       P19338; PRO_0000037577 [P27958]; Xeno; NbExp=4; IntAct=EBI-346967, EBI-6904388;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus. Cytoplasm. Note=Localized in
CC       cytoplasmic mRNP granules containing untranslated mRNAs.
CC   -!- PTM: Some glutamate residues are glycylated by TTLL8. This modification
CC       occurs exclusively on glutamate residues and results in a glycine chain
CC       on the gamma-carboxyl group (By similarity). {ECO:0000250}.
CC   -!- PTM: Symmetrically methylated by PRMT5. {ECO:0000269|PubMed:21081503}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC03738.1; Type=Miscellaneous discrepancy; Note=Unlikely isoform. Aberrant splice sites.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M60858; AAA59954.1; -; Genomic_DNA.
DR   EMBL; AK091742; BAC03738.1; ALT_SEQ; mRNA.
DR   EMBL; AC017104; AAY24247.1; -; Genomic_DNA.
DR   CCDS; CCDS33397.1; -.
DR   PIR; A35804; A35804.
DR   PIR; S53728; S53728.
DR   RefSeq; NP_005372.2; NM_005381.2.
DR   PDB; 2FC8; NMR; -; A=564-652.
DR   PDB; 2FC9; NMR; -; A=478-565.
DR   PDB; 2KRR; NMR; -; A=300-466.
DR   PDBsum; 2FC8; -.
DR   PDBsum; 2FC9; -.
DR   PDBsum; 2KRR; -.
DR   AlphaFoldDB; P19338; -.
DR   SMR; P19338; -.
DR   BioGRID; 110771; 737.
DR   CORUM; P19338; -.
DR   DIP; DIP-89N; -.
DR   ELM; P19338; -.
DR   IntAct; P19338; 184.
DR   MINT; P19338; -.
DR   STRING; 9606.ENSP00000318195; -.
DR   ChEMBL; CHEMBL4295725; -.
DR   MoonProt; P19338; -.
DR   GlyCosmos; P19338; 4 sites, 1 glycan.
DR   GlyGen; P19338; 5 sites, 1 O-linked glycan (5 sites).
DR   iPTMnet; P19338; -.
DR   MetOSite; P19338; -.
DR   PhosphoSitePlus; P19338; -.
DR   SwissPalm; P19338; -.
DR   BioMuta; NCL; -.
DR   DMDM; 90110781; -.
DR   DOSAC-COBS-2DPAGE; P19338; -.
DR   SWISS-2DPAGE; P19338; -.
DR   CPTAC; CPTAC-936; -.
DR   EPD; P19338; -.
DR   jPOST; P19338; -.
DR   MassIVE; P19338; -.
DR   MaxQB; P19338; -.
DR   PaxDb; P19338; -.
DR   PeptideAtlas; P19338; -.
DR   ProteomicsDB; 53647; -.
DR   TopDownProteomics; P19338; -.
DR   ABCD; P19338; 5 sequenced antibodies.
DR   Antibodypedia; 3779; 948 antibodies from 42 providers.
DR   DNASU; 4691; -.
DR   Ensembl; ENST00000322723.9; ENSP00000318195.4; ENSG00000115053.17.
DR   GeneID; 4691; -.
DR   KEGG; hsa:4691; -.
DR   MANE-Select; ENST00000322723.9; ENSP00000318195.4; NM_005381.3; NP_005372.2.
DR   UCSC; uc002vru.4; human.
DR   AGR; HGNC:7667; -.
DR   CTD; 4691; -.
DR   DisGeNET; 4691; -.
DR   GeneCards; NCL; -.
DR   HGNC; HGNC:7667; NCL.
DR   HPA; ENSG00000115053; Low tissue specificity.
DR   MIM; 164035; gene.
DR   neXtProt; NX_P19338; -.
DR   OpenTargets; ENSG00000115053; -.
DR   PharmGKB; PA31469; -.
DR   VEuPathDB; HostDB:ENSG00000115053; -.
DR   eggNOG; KOG0123; Eukaryota.
DR   GeneTree; ENSGT00940000157437; -.
DR   HOGENOM; CLU_026300_1_0_1; -.
DR   InParanoid; P19338; -.
DR   OrthoDB; 5482496at2759; -.
DR   PhylomeDB; P19338; -.
DR   TreeFam; TF328499; -.
DR   PathwayCommons; P19338; -.
DR   Reactome; R-HSA-6791226; Major pathway of rRNA processing in the nucleolus and cytosol.
DR   SignaLink; P19338; -.
DR   SIGNOR; P19338; -.
DR   BioGRID-ORCS; 4691; 716 hits in 1171 CRISPR screens.
DR   ChiTaRS; NCL; human.
DR   EvolutionaryTrace; P19338; -.
DR   GenomeRNAi; 4691; -.
DR   Pharos; P19338; Tbio.
DR   PRO; PR:P19338; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P19338; protein.
DR   Bgee; ENSG00000115053; Expressed in ventricular zone and 98 other tissues.
DR   ExpressionAtlas; P19338; baseline and differential.
DR   Genevisible; P19338; HS.
DR   GO; GO:0005938; C:cell cortex; IDA:UniProtKB.
DR   GO; GO:0005694; C:chromosome; IDA:HPA.
DR   GO; GO:0001533; C:cornified envelope; IEA:Ensembl.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:CACAO.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IDA:UniProtKB.
DR   GO; GO:0005681; C:spliceosomal complex; IBA:GO_Central.
DR   GO; GO:0044547; F:DNA topoisomerase binding; IPI:CAFA.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IEA:Ensembl.
DR   GO; GO:0048027; F:mRNA 5'-UTR binding; IDA:CAFA.
DR   GO; GO:0042731; F:PH domain binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0042162; F:telomeric DNA binding; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IDA:UniProtKB.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl.
DR   GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0017148; P:negative regulation of translation; IMP:CAFA.
DR   GO; GO:0048026; P:positive regulation of mRNA splicing, via spliceosome; IBA:GO_Central.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:1901838; P:positive regulation of transcription of nucleolar large rRNA by RNA polymerase I; IMP:UniProtKB.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   CDD; cd12403; RRM1_NCL; 1.
DR   CDD; cd12404; RRM2_NCL; 1.
DR   CDD; cd12405; RRM3_NCL; 1.
DR   CDD; cd12406; RRM4_NCL; 1.
DR   Gene3D; 3.30.70.330; -; 4.
DR   InterPro; IPR034230; Nucleolin_RRM1.
DR   InterPro; IPR034233; Nucleolin_RRM2.
DR   InterPro; IPR034234; Nucleolin_RRM3.
DR   InterPro; IPR034235; Nucleolin_RRM4.
DR   InterPro; IPR012677; Nucleotide-bd_a/b_plait_sf.
DR   InterPro; IPR035979; RBD_domain_sf.
DR   InterPro; IPR000504; RRM_dom.
DR   InterPro; IPR003954; RRM_dom_euk.
DR   PANTHER; PTHR23236; EUKARYOTIC TRANSLATION INITIATION FACTOR 4B/4H; 1.
DR   PANTHER; PTHR23236:SF100; NUCLEOLIN; 1.
DR   Pfam; PF00076; RRM_1; 4.
DR   SMART; SM00360; RRM; 4.
DR   SMART; SM00361; RRM_1; 2.
DR   SUPFAM; SSF54928; RNA-binding domain, RBD; 3.
DR   PROSITE; PS50102; RRM; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cytoplasm; Direct protein sequencing;
KW   DNA-binding; Isopeptide bond; Methylation; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; RNA-binding; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:7718615"
FT   CHAIN           2..710
FT                   /note="Nucleolin"
FT                   /id="PRO_0000081691"
FT   REPEAT          58..65
FT                   /note="1"
FT   REPEAT          75..82
FT                   /note="2"
FT   REPEAT          83..90
FT                   /note="3"
FT   REPEAT          91..98
FT                   /note="4"
FT   REPEAT          99..104
FT                   /note="5; truncated"
FT   REPEAT          105..112
FT                   /note="6"
FT   REPEAT          120..127
FT                   /note="7"
FT   REPEAT          128..135
FT                   /note="8"
FT   DOMAIN          307..383
FT                   /note="RRM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          393..466
FT                   /note="RRM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          486..560
FT                   /note="RRM 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   DOMAIN          572..647
FT                   /note="RRM 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00176"
FT   REGION          1..303
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          58..135
FT                   /note="8 X 8 AA tandem repeats of X-T-P-X-K-K-X-X"
FT   REGION          640..710
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        24..43
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        145..171
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        184..210
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        234..272
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        273..299
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         9
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         15
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09405"
FT   MOD_RES         16
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09405"
FT   MOD_RES         28
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         34
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         41
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         42
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         67
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         69
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   MOD_RES         76
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17924679,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         84
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         92
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         96
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09405"
FT   MOD_RES         99
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         102
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         106
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         109
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09405"
FT   MOD_RES         113
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         116
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         121
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:17924679,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         124
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         145
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:17487921, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         153
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:17487921, ECO:0007744|PubMed:23186163"
FT   MOD_RES         184
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17487921,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         206
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17487921,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         214
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         301
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         318
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         348
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09405"
FT   MOD_RES         356
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         367
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         377
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         398
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         403
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         405
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         427
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09405"
FT   MOD_RES         444
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09405"
FT   MOD_RES         458
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         460
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         467
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09405"
FT   MOD_RES         477
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09405"
FT   MOD_RES         513
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         521
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P09405"
FT   MOD_RES         563
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         572
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         577
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         580
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         591
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         619
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         646
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         656
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P08199"
FT   MOD_RES         660
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P08199"
FT   MOD_RES         666
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P08199"
FT   MOD_RES         670
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P08199"
FT   MOD_RES         673
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P08199"
FT   MOD_RES         679
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P08199"
FT   MOD_RES         681
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P08199"
FT   MOD_RES         687
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P08199"
FT   MOD_RES         691
FT                   /note="Asymmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P08199"
FT   MOD_RES         694
FT                   /note="Asymmetric dimethylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P08199"
FT   MOD_RES         694
FT                   /note="Omega-N-methylarginine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P09405"
FT   CROSSLNK        297
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        297
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        324
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        324
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        370
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        377
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        513
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        577
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        589
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        589
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        624
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VARIANT         68
FT                   /note="P -> L (in dbSNP:rs11542691)"
FT                   /id="VAR_046353"
FT   VARIANT         122
FT                   /note="P -> L (in dbSNP:rs11542687)"
FT                   /id="VAR_046354"
FT   VARIANT         174
FT                   /note="A -> V (in dbSNP:rs11542689)"
FT                   /id="VAR_046355"
FT   CONFLICT        549
FT                   /note="E -> G (in Ref. 3; BAC03738)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        623..626
FT                   /note="Missing (in Ref. 2; AAA59954)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        625..627
FT                   /note="Missing (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   STRAND          304..306
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   STRAND          308..312
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   STRAND          316..318
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   HELIX           321..333
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   STRAND          338..343
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   STRAND          345..356
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   HELIX           357..365
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   STRAND          377..379
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   HELIX           388..391
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   STRAND          394..399
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   HELIX           406..413
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   STRAND          416..424
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   STRAND          427..435
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   HELIX           439..442
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   TURN            443..445
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   HELIX           446..449
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   STRAND          460..463
FT                   /evidence="ECO:0007829|PDB:2KRR"
FT   STRAND          486..492
FT                   /evidence="ECO:0007829|PDB:2FC9"
FT   HELIX           499..505
FT                   /evidence="ECO:0007829|PDB:2FC9"
FT   STRAND          510..513
FT                   /evidence="ECO:0007829|PDB:2FC9"
FT   STRAND          518..520
FT                   /evidence="ECO:0007829|PDB:2FC9"
FT   STRAND          524..529
FT                   /evidence="ECO:0007829|PDB:2FC9"
FT   HELIX           533..542
FT                   /evidence="ECO:0007829|PDB:2FC9"
FT   STRAND          544..548
FT                   /evidence="ECO:0007829|PDB:2FC9"
FT   STRAND          551..557
FT                   /evidence="ECO:0007829|PDB:2FC9"
FT   STRAND          565..568
FT                   /evidence="ECO:0007829|PDB:2FC8"
FT   STRAND          572..577
FT                   /evidence="ECO:0007829|PDB:2FC8"
FT   HELIX           585..590
FT                   /evidence="ECO:0007829|PDB:2FC8"
FT   STRAND          596..602
FT                   /evidence="ECO:0007829|PDB:2FC8"
FT   STRAND          604..606
FT                   /evidence="ECO:0007829|PDB:2FC8"
FT   STRAND          608..616
FT                   /evidence="ECO:0007829|PDB:2FC8"
FT   HELIX           620..630
FT                   /evidence="ECO:0007829|PDB:2FC8"
FT   STRAND          641..644
FT                   /evidence="ECO:0007829|PDB:2FC8"
FT   STRAND          650..652
FT                   /evidence="ECO:0007829|PDB:2FC8"
SQ   SEQUENCE   710 AA;  76614 MW;  C97F6E34E5CA6727 CRC64;
     MVKLAKAGKN QGDPKKMAPP PKEVEEDSED EEMSEDEEDD SSGEEVVIPQ KKGKKAAATS
     AKKVVVSPTK KVAVATPAKK AAVTPGKKAA ATPAKKTVTP AKAVTTPGKK GATPGKALVA
     TPGKKGAAIP AKGAKNGKNA KKEDSDEEED DDSEEDEEDD EDEDEDEDEI EPAAMKAAAA
     APASEDEDDE DDEDDEDDDD DEEDDSEEEA METTPAKGKK AAKVVPVKAK NVAEDEDEEE
     DDEDEDDDDD EDDEDDDDED DEEEEEEEEE EPVKEAPGKR KKEMAKQKAA PEAKKQKVEG
     TEPTTAFNLF VGNLNFNKSA PELKTGISDV FAKNDLAVVD VRIGMTRKFG YVDFESAEDL
     EKALELTGLK VFGNEIKLEK PKGKDSKKER DARTLLAKNL PYKVTQDELK EVFEDAAEIR
     LVSKDGKSKG IAYIEFKTEA DAEKTFEEKQ GTEIDGRSIS LYYTGEKGQN QDYRGGKNST
     WSGESKTLVL SNLSYSATEE TLQEVFEKAT FIKVPQNQNG KSKGYAFIEF ASFEDAKEAL
     NSCNKREIEG RAIRLELQGP RGSPNARSQP SKTLFVKGLS EDTTEETLKE SFDGSVRARI
     VTDRETGSSK GFGFVDFNSE EDAKAAKEAM EDGEIDGNKV TLDWAKPKGE GGFGGRGGGR
     GGFGGRGGGR GGRGGFGGRG RGGFGGRGGF RGGRGGGGDH KPQGKKTKFE
//
